key: cord-0706284-5gbev6u4
authors: Stein, David; Oviedo-Orta, Ernesto; Kampman, Wendy A; McGinniss, Jennifer; Betts, George; McDermott, Margaret; Holly, Beth; Lancaster, Johnathan M; Braunstein, Ned; Yancopoulos, George D; Weinreich, David M
title: Compassionate Use of REGEN-COV (®) in Patients with COVID-19 and Immunodeficiency-Associated Antibody Disorders
date: 2021-12-31
journal: Clin Infect Dis
DOI: 10.1093/cid/ciab1059
sha: 1a85da9812134ab9b12f2639ed7f67a0840d3f94
doc_id: 706284
cord_uid: 5gbev6u4

BACKGROUND: Patients with immunodeficiency-associated antibody disorders are at a higher risk of prolonged/persistent COVID-19 infection, having no viable treatment options. METHODS: A retrospective analysis of patients with primary and/or secondary immunodeficiency-associated antibody disorders who received casirivimab and imdevimab (REGEN-COV (®)) under emergency compassionate use. OBJECTIVES: describe safety and response to REGEN-COV, focusing on the subset of patients who had COVID-19 duration ≥21 days before treatment. RESULTS: Quantitative (change in oxygenation status and/or viral load) and/or qualitative (physician-reported clinical status) patient outcomes data are reported from 64 patients who received REGEN-COV. Improvement in ≥1 outcome was observed in 90.6% of the overall patient group. Thirty-seven of these had COVID-19 duration ≥21 days before treatment; median time from diagnosis to REGEN-COV was 60.5 days. Of the 29 patients with COVID-19 duration ≥21 days before treatment and available outcome data, 96.6% showed improvement in ≥1 outcome. In the 14 patients with post-treatment RT-PCR results available, 11 (78.6%) reported a negative RT-PCR following treatment, with 5 (45.5%) reporting a negative RT-PCR within 5 days and 8 (72.7%) within 21 days of treatment. Ten of 85 patients (11.8%) experienced serious adverse events, only one was an infusion-related reaction, possibly related to REGEN-COV. Two deaths were reported, neither were attributed to REGEN-COV. CONCLUSIONS: In this retrospective analysis of immunodeficient patients granted REGEN-COV under the compassionate use program, REGEN-COV treatment was associated with rapid viral clearance and clinical improvement in patients with long-standing COVID-19. Adverse events were consistent with COVID-19 and its associated complications, and due to patients’ concurrent medical conditions.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causal agent of coronavirus disease 2019 (COVID- 19) , first emerged in 2019, and has led to a global pandemic. Patients infected with SARS-CoV-2 are at risk of developing a range of respiratory conditions, from mild to severe symptoms, and sometimes fatal illness [1] . Patients with either primary or secondary immunodeficiency-associated antibody disorders that have an inherited or acquired inability to produce antibodies against infective agents have a high risk of suffering from prolonged or persistent SARS-CoV-2 infection, increasing their morbidity and mortality risk [2] [3] [4] . These patients are also likely to show lack of, or significantly less effective, protective immune responses to vaccines [5] , and may have to rely on alternate prevention and treatment regimes.

The treatment of immunocompromised patients with COVID-19 using convalescent plasma is controversial due to lack of specificity and variable content of potent neutralizing antibodies [6] [7] [8] . In February 2021, the United States Food and Drug Administration issued a revision of the Emergency Use Authorization for COVID-19 convalescent plasma, for the treatment of hospitalized patients with COVID-19 who have impaired humoral immunity and cannot produce an adequate antibody response [9] . However, results from 3 small randomized controlled trials in patients with moderate-to-severe COVID-19 showed no significant differences in improved clinical outcomes between the convalescent plasmatreated and placebo groups [10] [11] [12] .

Casirivimab and imdevimab (REGEN-COV ® ) is a combination of 2 human, immunoglobulin G1 monoclonal antibodies (mAbs) that bind the receptor-binding domain of the SARS-CoV-2 spike protein and block interaction with angiotensin-converting enzyme 2 [13] . REGEN-COV targets separate non-overlapping epitopes thereby neutralizing SARS-CoV-2, with a reduced likelihood of viral escape due to genetic mutations [14] . Furthermore, this combination of mAbs has been shown to retain neutralization potency against multiple SARS-CoV-2 variants [14] . The blood levels of SARS-CoV-2 neutralizing activity that are A c c e p t e d M a n u s c r i p t achieved with REGEN-COV are approximately 10,000-to 100,000-fold higher than that achievable with high-titer convalescent plasma. Correspondingly, REGEN-COV has demonstrated convincing activity across multiple phase 2 and 3 studies and across the continuum of the disease, including pre-and post-exposure prophylaxis [15] , as well as in the treatment of both outpatients and hospitalized patients [16] [17] [18] [19] . Across these studies, the greatest benefit was observed in patients who had not yet developed their own adaptive immune response at baseline (ie, who did not make their own anti-SARS-CoV-2 antibodies and are thus termed "seronegative"); such high-risk seronegative patients may share characteristics with individuals with an immunodeficiency who cannot mount an antibody response.

Informed by the clinical data from REGEN-COV program, Regeneron has, with the approval of the FDA, been granting compassionate use to patients with COVID-19 and primary and/or secondary immune deficiencies. This retrospective analysis of such patients who received REGEN-COV under emergency compassionate use gathered data to provide a better understanding of clinical outcomes in this vulnerable group. While data for all patients (the overall patient group) are presented, we give particular focus to the subset of patients with COVID-19 duration ≥21 days prior to treatment, as this subset reflects those unable to effectively clear the virus.

This is a retrospective, descriptive data analysis using de-identified patient data from patients who received REGEN-COV under emergency compassionate use from 2 September 2020 to 29 March 2021. M a n u s c r i p t Further information and details about the compassionate use program can be found at https://www.regeneron.com/downloads/regeneron-compassionate-use-request.pdf.

The objective of this retrospective analysis was to describe safety and response to REGEN-COV in patients with primary and/or secondary immunodeficiency-associated antibody disorders that were evaluated and approved for drug use under compassionate use. Response to REGEN-COV is described using quantitative patient outcome data (change in oxygenation status and/or viral load) and/or qualitative patient outcome data (physicianreported clinical status). Serious adverse events and death were also evaluated.

Oxygenation status is described as oxygen requirement and correlated oxygen saturations. Viral load is described by either SARS-CoV-2 RT-PCR status (negative or positive) and/or cycle threshold (Ct) values in RT-PCR, prior to and after compassionate use of REGEN-COV. Descriptive safety data are also presented. Reporting of serious adverse events, adverse events of special interest (grade ≥2 infusion-related reactions, grade ≥2 A c c e p t e d M a n u s c r i p t hypersensitivity reactions), and pregnancy was a requirement for treatment under compassionate use.

The treating physician was responsible for compliance in accordance with the principles of the Declaration of Helsinki, International Council for Harmonisation Good Clinical Practice guidelines, and applicable regulatory requirements for administering an investigational product under compassionate use. The treating physician was also responsible for all safety reporting and regulatory obligations associated with the conduct of the compassionate use as required by applicable law. The institutional review board (WCG IRB, Puyallup, WA; IRB tracking number 20212896) found that this research met the requirements for a waiver of consent under 45 CFR 46 116(f) and 45 CFR 46.116(d). All patients provided written informed consent before receiving treatment.

In total, 174 patients from the US were evaluated and approved to receive REGEN-COV under the emergency compassionate use program as of 29 March 2021, of whom 95 (54.6%) had primary and/or secondary immunodeficiency-associated antibody disorders. Of these patients, 85 received intravenous REGEN-COV and data is available for 64 of these patients. Of the 64 patients with available data, 37 (43.5%) had COVID-19 duration ≥21 days prior to treatment.

In the subset of patients with COVID-19 duration ≥21 days prior to treatment, 64.9% were male, the mean age was 49.1 years (median: 52.0 years; min-max: 1-75), 27.0% were aged ≥65 years, and 27/37 (73.0%) were inpatients. The median time from RT-PCR diagnosis to administration of REGEN-COV was 60.5 days (min-max: 25-218; mean: 83.2 days). Three patients (8.1%) had primary immunodeficiency-associated antibody disorders, 34 patients (91.9%) had secondary causes of immunodeficiency-associated antibody disorders (malignant or drug induced); the most common causes included treatment with anti-CD20 A c c e p t e d M a n u s c r i p t (rituximab), acute lymphocytic leukemia, follicular lymphoma, diffuse B-cell lymphoma, and other non-Hodgkin's lymphomas (Table 1) .

Of the 37 patients with COVID-19 duration ≥21 days prior to treatment, qualitative or quantitative outcome data were available for 29 patients: 23 In the overall patient group, 62.4% were male, the mean age was 47.4 years (median: 52.0 years; min-max: 1-79), 24.7% of patients were aged ≥65 years, and the majority were inpatients (65/85; 76.5%). The median time from RT-PCR diagnosis to administration of REGEN-COV was 13.0 days (min-max: 1-218; mean: 40.8 days). Thirteen patients (15.3%) had primary (genetic) immunodeficiency-associated antibody disorders, and 72 (84.7%) had secondary causes of immunodeficiency-associated antibody disorders (malignant or druginduced) (Supplementary Table 1 A c c e p t e d M a n u s c r i p t Safety In the overall patient group, 10/85 patients (11.8%) experienced serious adverse events (SAEs; as defined by physician-completion of an SAE form), of which only 1 event was an infusion-related reaction judged as possibly related to REGEN-COV. No other SAEs were judged as possibly related to treatment with REGEN-COV. Two patients who experienced SAEs had a COVID-19 duration ≥21 days prior to treatment. There were 2 deaths reported, neither of which were attributed by the investigator to treatment with REGEN-COV: 1 from hypoxia; and 1 from respiratory failure secondary to chronic COVID-19 and diffuse alveolar hemorrhage complicated by pulmonary aspergillosis. The events reported were consistent with COVID-19 and its associated complications and due to patients' concurrent medical conditions.

Because immunocompromised patients cannot generate their own antibodies against SARS-CoV-2, whether by vaccination or natural infection, they represent a particularly vulnerable and high-risk population. Antibody-related treatments for SARS-CoV-2 -compensating for the lack of endogenous antibodies -are potentially viable treatment options, including polyclonal antibodies such as convalescent plasma [20] . However, the available clinical data have shown no efficacy in patients with COVID-19 when treated with convalescent plasma [10] [11] [12] , which generally has limited amounts of SARS-CoV-2 neutralizing antibody levels. In contrast, 10,000-100,000-fold higher levels of neutralizing activity can be achieved with recombinant antibody treatments such as REGEN-COV, which has demonstrated convincing activity across multiple phase 2 and 3 studies and across the continuum of the disease, including in high-risk seronegative patients who share some characteristics with individuals with an immunodeficiency who cannot mount an antibody response [15] [16] [17] [18] [19] .

Case reports have demonstrated treatment benefit with REGEN-COV in individual patients with primary and/or secondary immunodeficiencies, either alone or in combination with standard-of-care antiviral therapies [21] [22] [23] [24] [25] . Furthermore, in a report of 25 solid organ transfer outpatients with mild-to-moderate COVID-19, no patient experienced symptom progression or required hospitalization following treatment with REGEN-COV [24] .

Additionally, in a case report of a kidney transplant recipient with COVID-19 following poor response to vaccination, treatment with REGEN-COV led to seroconversion and improved clinical and virologic outcomes [26] . It is important to note that a third mRNA vaccination A c c e p t e d M a n u s c r i p t may improve the humoral response in some transplant patients, [27] and that additional vaccination may obviate the need for REGEN-COV in these patients. REGEN-COV treatment should not be utilized in place of vaccination, but rather as an alternative approach in those who show continued poor response to vaccination.

As far as we are aware, this is the first report describing outcomes following REGEN-COV treatment for COVID-19 in a series of patients with primary and/or secondary immunodeficiency-associated antibody disorders. In this retrospective analysis, 96.6% of patients with COVID-19 duration ≥21 days prior to treatment showed marked improvement in 1 or more qualitative and/or quantitative outcomes following compassionate use with REGEN-COV, with 85.7% showing improvement within 7 days of treatment. Most patients with evaluable RT-PCR data during follow-up showed rapid reductions in viral load, despite many having prolonged duration of infection prior to administration of REGEN-COV.

It is, however, important to interpret the data presented in context. The majority of patients in this report were treated before vaccines were widely available, and before antibody testing was widely utilized. Furthermore, given this is a case series of patients treated under compassionate use, and not a clinical trial, there is no comparator group and we cannot account for bias. Additionally, there was no standard of practice on when to repeat PCR post-treatment, nor were there prespecified data collection parameters. We can therefore only report results based on the data captured at the discretion of the treating physician.

This case series provides data which are consistent with the totality of the data from phase 2 and 3 studies of REGEN-COV [15] [16] [17] [18] [19] , in which the greatest benefit with REGEN-COV was seen in high-risk patients who had not yet mounted their own antibody response, and A c c e p t e d M a n u s c r i p t Notes M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t 

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

COVID-19 in persons with haematological cancers

Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19

COVID-19: consider cytokine storm syndromes and immunosuppression

A review of vaccinations in adult patients with secondary immunodeficiency

A review of COVID-19 convalescent plasma use in COVID-19 with focus on proof of efficacy

Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19: A Systematic Review and Metaanalysis

A little) clarity on convalescent plasma for Covid-19

Fact sheet for health care providers Emergency Use Authorization (EUA) of COVID-19 convalescent plasma for treatment of hospitalized patients with COVID-19

Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)

Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: A randomized clinical trial

A randomized trial of convalescent plasma in Covid-19 severe pneumonia

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

Subcutaneous REGEN-COV antibody combination to prevent Covid-19

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label

REGEN-COV antibody cocktail in outpatients with Covid-19. medRxiv

REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19

REGEN-COV antibody combination and outcomes in outpatients with Covid-19

The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis

Successful clearance of 300 day SARS-CoV-2 infection in a subject with B-cell depletion associated prolonged (B-DEAP) COVID by REGEN-COV anti-spike monoclonal antibody cocktail

Successful treatment of persistent coronavirus disease 2019 infection in a patient with hypogammaglobulinemia with REGN-COV2: A case report

Treatment of SARS-CoV-2 relapse with remdesivir and neutralizing antibodies cocktail in a patient with X-linked agammaglobulinaemia

Casirivimab-imdevimab for treatment of COVID-19 in solid organ transplant recipients: An early experience

A programmatic response, including bamlanivimab or casirivimab-imdevimab administration, reduces hospitalization and death in COVID-19 positive abdominal transplant recipients

Better late than never: eventual seroconversion against SARS-CoV-2 in a kidney transplant recipient after repeated immune challenge and monoclonal antibody therapy

A third injection of the BNT162b2 mRNA COVID-19 vaccine in kidney transplant recipients improves the humoral immune response

Fact sheet for health care providers Emergency Use Authorization (EUA) of REGEN-COV TM (casirivimab and imdevimab)

The authors would like to thank the patients, their families, and the physicians involved in this work, as well as Caryn Trbovic, PhD, from Regeneron Pharmaceuticals for medical writing support; and Prime, Knutsford, UK, for formatting and copy-editing suggestions and for assistance with development of the manuscript. 

A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t